Some opportunities of using xanthine oxidase inhibitors
https://doi.org/10.14412/1996-7012-2019-1-114-120
Abstract
The review presents modern concepts of the role of xanthine oxidase (XO) in the pathogenesis of a number of diseases. It has been shown that XO activity can be associated with the development and progression not only of gout, but, possibly, diabetes mellitus, hypertension, and other cardiovascular diseases.
The paradigm of an association of hyperuricemia (HU) with cardiovascular and chronic renal diseases has undergone certain changes — from skepticism to obtaining the evidence of its serious negative impact. Moreover, XO has been established to be a key enzyme involved in the synthesis of uric acid (UA) as a final adenine nucleotides metabolite, and is extensively present in various organs (the liver, intestine, lung, kidneys, heart, and brain) and in plasma. XO plays an important role in the synthesis not only of UA, but also in that of superoxide free radicals. There are two possible mechanisms linking metabolism and inflammation, in which UA is involved: inflammation activated by UA crystallization and generation of superoxide free radicals during its synthesis. The role of reactive oxygen species is discussed in a number of pathological conditions: induction of apoptosis/necrosis, inhibition of expression of many genes, activation of cell signaling cascades, oxidative damage to DNA and lipids, inflammation, metabolic disorders, atherosclerosis, etc. Inhibition of these mechanisms leads to a decrease in the synthesis and accumulation of UA in the bones, joints and other tissues. Accordingly, XO is a confirmed target for the treatment of gout, and, possibly, other HU-associated conditions. After introduction of a new XO inhibitor (iXO) into clinical practice, the target level of UA has can be achieved by more than 80% of patients with gout. So there is a growing interest in the assessment of the potentials of iXO for the treatment of different pathological conditions.
About the Authors
O. V. ZhelyabinaRussian Federation
Olga Vladimirovna Zhelyabina
34A, Kashirskoe Shosse, Moscow 115522
M. S. Eliseev
Russian Federation
34A, Kashirskoe Shosse, Moscow 115522
References
1. Kratzer JT, Lanaspa MA, Murphy MN, et al. Evolutionary history and metabolic insights of ancient mammalian uricases. Proc Natl Acad Sci U S A. 2014 Mar П;Ш(10): 3763-8. doi: 10.1073/pnas.1320393111. Epub 2014 Feb 18.
2. Dhiman R, Sharma S, Singh G, et al. Design and synthesis of aza-flavones as a new class of xanthine oxidase inhibitors. Arch Pharm (Weinheim). 2013 Jan;346(1):7-16. doi: 10.1002/ardp.201200296. Epub 2012 Oct 18.
3. Nepali K, Agarwal A, Sapra S, et al. N-(1,3-Diaryl-3-oxopropyl)-amides as a new template for xanthine oxidase inhibitors. BioorgMedChem. 2011 Sep 15;19(18): 5569-76. doi: 10.1016/j.bmc.2011.07.039. Epub 2011 Jul 26.
4. Lin S, Zhang G, Pan J, Gong D. Deciphering the inhibitory mechanism of genistein on xanthine oxidase in vitro. J Photochem Photobiol B. 2015 Dec;153: 463-72. doi: 10.1016/j.jphotobi-ol.2015.10.022. Epub 2015 Nov 11.
5. Radi R, Rubbo H, Bush K, et al. Xanthine oxidase binding to glycosaminoglycans: kinetics and superoxide dismutase interactions of immobilized xanthine oxidase-heparin complexes. Arch Biochem Biophys. 1997 Mar 1; 339(1):125-35.
6. Ojha R, Singh J, Ojha A, et al. An updated patent review: xanthine oxidase inhibitors for the treatment of hyperuricemia and gout (2011-2015). Expert Opin Ther Pat. 2017 Mar; 27(3):311-345. doi: 10.1080/13543776.2017.1261111. Epub 2016 Nov 28.
7. Richette P, Doherty M, Pascual E, et al. 2016 updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 2017 Jan;76(1):29-42. doi: 10.1136/annrheumdis-2016-209707. Epub 2016 Jul 25.
8. Schumacher HR, Becker MA, Lloyd E, et al. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford). 2009 Feb;48(2):188-94. doi: 10.1093/rheumatology/ken457.
9. Singh JA, Akhras KS, Shiozawa A. Comparative effectiveness of urate lowering with febuxostat versus allopurinol in gout: analyses from large U.S. managed care cohort. Arthritis Res Ther. 2015 May 12; 17:120. doi: 10.1186/s13075-015-0624-3.
10. Becker MA, Schumacher HR, MacDonald PA, et al. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. J Rheumatol. 2009 Jun;36(6):1273-82. doi: 10.3899/jrheum.080814. Epub 2009 Mar 13.
11. Kiltz U, Smolen J, Bardin T, et al. Treat-to-target (T2T) recommendations for gout. Ann Rheum Dis. 2017 Apr;76(4): 632-638. doi: 10.1136/annrheumdis-2016-209467. Epub 2016 Sep 22.
12. Hao G, Duan W, Sun J, et al. Effects of febuxostat on serum cytokines IL-1, IL-4, IL-6, IL-8, TNF-a and COX-2. Exp Ther Med. 2019 Jan;17(1):812-816. doi: 10.3892/etm.2018.6972. Epub 2018 Nov 15.
13. Gondouin B, Jourde-Chiche N, Sallee M, et al. Plasma Xanthine Oxidase Activity Is Predictive of Cardiovascular Disease in Patients with Chronic Kidney Disease, Independently of Uric Acid Levels. Nephron. 2015;131(3):167-74. doi: 10.1159/000441091. Epub 2015 Oct 2.
14. Eleftheriadis T, Pissas G, Liakopoulos V, et al. Xanthine oxidase inhibitors may prevent or slow chronic kidney disease even in the absence of hyperuricemia. Kidney Int. 2018 Oct;94(4):830-831. doi: 10.1016/j.kint.2018.06.019.
15. Vogt L, Waanders F, Boomsma F, et al. Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losar-tan. J Am Soc Nephrol. 2008 May;19(5): 999-1007. doi: 10.1681/ASN.2007060693. Epub 2008 Feb 13.
16. Slagman MC, Waanders F, Hemmelder MH, et al. Moderate dietary sodium restriction added to angiotensin converting enzyme inhibition compared with dual blockade in lowering proteinuria and blood pressure: Randomised controlled trial. BMJ. 2011 Jul 26;343:d4366. doi: 10.1136/bmj.d4366.
17. Cheng J, Zhang X, Tian J, et al. Combination therapy an ACE inhibitor and an angiotensin receptor blocker for IgA nephropathy: A meta-analysis. Int J Clin Pract. 2012 Oct;66(10):917-23. doi: 10.1111/j.1742-1241.2012.02970.x.
18. Lv J, Xu D, Perkovic V, et al. Corticosteroid therapy in IgA nephropathy. J Am Soc Nephrol. 2012 Jun;23(6):1108-16. doi: 10.1681/ASN.2011111112. Epub 2012 Apr 26.
19. Inoue MK, Yamamotoya T, Nakatsu Y, et al. The Xanthine Oxidase Inhibitor Febuxostat Suppresses the Progression of IgA Nephropathy, Possibly via Its AntiInflammatory and Anti-Fibrotic Effects in the gddY Mouse Model. Int J Mol Sci. 2018 Dec 10;19(12). pii: E3967. doi: 10.3390/ijms19123967.
20. Sarvepalli PS, Fatima M, Quadri AK, et al. Study of therapeutic efficacy of febuxostat in chronic kidney disease stage IIIA to stage VD. Saudi J Kidney Dis Transpl. 2018 Sep-Oct;29(5):1050-1056. doi: 10.4103/1319-2442.243953.
21. Higgins P, Dawson J, Lees KR, et al. Xanthine oxidase inhibition for the treatment of cardiovascular disease: a systematic review and meta-analysis. Cardiovasc Ther. 2012 Aug; 30(4):217-26. doi: 10.1111/j.1755-5922.2011.00277.x. Epub 2011 Jun 12.
22. Scheepers LE, Wei FF, Stolarz-Skrzypek K, et al. Xanthine oxidase gene variants and their association with blood pressure and incident hypertension: a population study. JHypertens. 2016 Nov;34(11): 2147-54. doi: 10.1097/HJH.0000000000001077.
23. Scheepers LE, Boonen A, Pijnenburg W, et al. Associations of plasma uric acid and purine metabolites with blood pressure in children: the KOALA Birth Cohort Study. JHypertens. 2017 May;35(5):982-993. doi: 10.1097/HJH.0000000000001270.
24. Khanna D, Fitzgerald JD, Khanna PP, et al; American College of Rheumatology. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken). 2012 Oct;64(10):1431-46. doi: 10.1002/acr.21772.
25. Sivera F, Andres M, Carmona L, et al. Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. Ann Rheum Dis. 2014 Feb;73(2):328-35. doi: 10.1136/annrheumdis-2013-203325. Epub 2013 Jul 18.
26. Eliseev MS. Cardiovascular safety of febuxostat. Analysis of the CARES study. Analiz issledovaniya CARES. Sovremennaya Revmatologiya= Modern Rheumatology Journal. 2018; 12(4):42-6. (In Russ.). doi: 10.14412/1996-7012-2018-4-42-46.
27. Perez-Ruiz F. Failure to Reach Serum Urate Target Is Associated with Elevated Mortality in Gout. Arthritis Rreum. 2018; 70(Suppl 9):954-5.
28. Nomura J, Busso N, Ives A, et al. Xanthine Oxidase Inhibition by Febuxostat Attenuates Experimental Atherosclerosis in Mice. SciRep. 2014 Apr 1;4:4554. doi: 10.1038/srep04554.
29. Yoshizawa T, Niwano S, Niwano H, et al. Antiremodeling Effect of Xanthine Oxidase Inhibition in a Canine Model of Atrial Fibrillation. Int Heart J. 2018 Sep 26;59(5): 1077-1085. doi: 10.1536/ihj.17-391. Epub 2018 Aug 29.
30. Kondo M, Imanishi M, Fukushima K, et al. Xanthine Oxidase Inhibition by Febuxostat in Macrophages Suppresses Angiotensin II-Induced Aortic Fibrosis. Am J Hypertens. 2019 Feb 12;32(3):249-256. doi: 10.1093/ajh/hpy157.
31. Kojima S, Matsui K, Ogawa H, et al. Febuxostat for Cerebral and Cardiorenovascular Events Prevention Study (FREED) investigators. Rationale, design, and baseline characteristics of a study to evaluate the effect of febuxostat in preventing cerebral, cardiovascular, and renal events in patients with hyperuricemia. J Cardiol. 2017 Jan;69(1):169-175. doi: 10.1016/j.jjcc.2016.02.015. Epub 2016 Apr 20.
32. MacDonald TM, Ford I, Nuki G, et al. Protocol of the Febuxostat versus Allopurinol Streamlined Trial (FAST): a large prospective, randomised, open, blinded endpoint study comparing the cardiovascular safety of allopurinol and febuxostat in the management of symptomatic hyperuricaemia. BMJ Open. 2014 Jul 10;4(7):e005354. doi: 10.1136/bmjopen-2014-005354.
33. Li C, Hsieh MC, Chang SJ. Metabolic syndrome, diabetes, and hyperuricemia. Curr Opin Rheumatol. 2013 Mar;25(2):210-6. doi: 10.1097/BOR.0b013e32835d951e.
34. Xu C, Yu C, Xu L, et al. High serum uric acid increases the risk for nonalcoholic fatty liver disease: a prospective observational study. PLoSOne. 2010 Jul 14;5(7):e11578. doi: 10.1371/journal.pone.0011578.
35. Ryu S, Chang Y, Kim SG, et al. Serum uric acid levels predict incident nonalcoholic fatty liver disease in healthy Korean men. Metabolism. 2011 Jun;60(6):860-6. doi: 10.1016/j.metabol.2010.08.005. Epub 2010 Sep 21.
36. Li Y, Xu C, Yu C, et al. Association of serum uric acid level with non-alcoholic fatty liver disease: a cross-sectional study. J Hepatol. 2009 May;50(5):1029-34. doi: 10.1016/j.jhep.2008.11.021. Epub 2009 Jan 9.
37. Afzali A, Weiss NS, Boyko EJ, et al. Association between serum uric acid level and chronic liver disease in the United States Hepatology. 2010 Aug;52(2):578-89. doi: 10.1002/hep.23717.
38. Nakatsu Y, Seno Y, Kushiyama A, et al. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model. Am J Physiol Gastrointest Liver Physiol. 2015 Jul 1; 309(1):G42-51. doi: 10.1152/ajpgi.00443.2014. Epub 2015 May 21.
39. Novichkova GA, Ptushkin VV, Rumyantsev AG. Clinical guidelines for the prevention and treatment of tumor lysis syndrome in children and adolescents. Rossiiskii zhurnal detskoi gematologii i onkologii. 2014;(1):37-50. (In Russ.). doi: 10.17650/2311-1267-2014-0-1-37-50.
40. Kishimoto K, Kobayashi R, Hori D, et al. Febuxostat as a Prophylaxis for Tumor Lysis Syndrome in Children with Hematological Malignancies. Anticancer Res. 2017 Oct; 37(10):5845-5849. doi: 10.21873/anticanres.12028.
41. Ramos MFP, Monteiro de Barros ADCM, Razvickas CV, et al. Xanthine oxidase inhibitors and sepsis. Int J Immunopathol Pharmacol. 2018 Jan-Dec;32:2058738418772210. doi: 10.1177/2058738418772210.
42. Ahmed MAE, Morsy EM, Ahmed AA. Protective effects of febuxostat against paraquat-induced lung toxicity in rats: Impact on RAGE/PI3K/Akt pathway and downstream inflammatory cascades. Life Sci. 2019 Feb 3. pii: S0024-3205(19)30085-2. doi: 10.1016/j.lfs.2019.02.007. [Epub ahead of print].
43. Morbini P, Villa C, Campo I, Zorzetto M, et al. The receptor for advanced glycation end products and its ligands: a new inflammatory pathway in lung disease? Mod Pathol. 2006 Nov; 19(11):1437-45. Epub 2006 Aug 25.
44. Chinnery PF. Mitochondrial disease in adults: what's old and what's new? EMBO Mol Med. 2015 Dec;7(12):1503-12. doi: 10.15252/emmm.201505079.
45. Kamatani N, Hashimoto M, Sakurai K, et al. Clinical studies on changes in purine compounds in blood and urine by the simultaneous administration of febuxostat and ino-sine, or by single administration of each. Gout NuclAcidMetab. 2017;41:171-81.
46. Kamatani N, Kushiyama A, Toyo-Oka L, Toyo-Oka T. Treatment of two mitochondrial disease patients with a combination of febux-ostat and inosine that enhances cellular ATP. J Hum Genet. 2019 Apr;64(4):351-353. doi: 10.1038/s10038-018-0558-0. Epub 2019 Jan 10.
47. Cantu-Medellin N, Kelley EE. Xanthine oxidoreductase-catalyzed reactive species generation: A process in critical need of reevaluation. Redox Biol. 2013 Jun 10;1:353-8. doi: 10.1016/j.redox.2013.05.002.
Review
For citations:
Zhelyabina OV, Eliseev MS. Some opportunities of using xanthine oxidase inhibitors. Sovremennaya Revmatologiya=Modern Rheumatology Journal. 2019;13(1):114-120. (In Russ.) https://doi.org/10.14412/1996-7012-2019-1-114-120